

2015

A global map of hemispheric influenza vaccine recommendations based on local patterns of viral circulation

Wladimir J. Alonso

Christine Yu


Cecile Viboud

Stephanie A. Richard

Cynthia Schuck-Paim

See next page for additional authors

Follow this and additional works at: http://hsrc.himmelfarb.gwu.edu/sphhs_global_facpubs

 Part of the [Influenza Humans Commons](#), [Influenza Virus Vaccines Commons](#), and the [International Public Health Commons](#)

Recommended Citation

Alonso, W.J., Yu, C., Viboud, C., Richard, S.A., Schuck-Paim, C., Simonsen, L., Miller, M.A. (2015). A global map of hemispheric influenza vaccine recommendations based on local patterns of viral circulation. *Scientific Reports*, 5:17214. doi:10.1038/srep17214

This Journal Article is brought to you for free and open access by the Global Health at Health Sciences Research Commons. It has been accepted for inclusion in Global Health Faculty Publications by an authorized administrator of Health Sciences Research Commons. For more information, please contact hsrc@gwu.edu.

Authors

Wladimir J. Alonso, Christine Yu, Cecile Viboud, Stephanie A. Richard, Cynthia Schuck-Paim, Lone Simonsen, Wyller A. Mello, and Mark A. Miller

SCIENTIFIC REPORTS



OPEN

A global map of hemispheric influenza vaccine recommendations based on local patterns of viral circulation

Wladimir J. Alonso¹, Christine Yu³, Cecile Viboud¹, Stephanie A. Richard¹, Cynthia Schuck-Paim², Lone Simonsen³, Wyller A. Mello⁴ & Mark A. Miller¹

Received: 26 August 2015

Accepted: 27 October 2015

Published: 01 December 2015

Both the Northern and the Southern Hemisphere annual WHO influenza vaccine recommendations are designed to ensure vaccine delivery before the winter-time peak of viral circulation in each hemisphere. However, influenza seasonal patterns are highly diverse in tropical countries and may be out of phase with the WHO recommendations for their respective hemisphere. We modelled the peak timing of influenza activity for 125 countries using laboratory-based surveillance data from the WHO's FLUNET database and compared it with the influenza hemispheric recommendations in place. Influenza vaccine recommendations for respectively 25% and 39% of the Northern and Southern Hemisphere countries were out of phase with peak influenza circulation in their corresponding hemisphere (62% and 53%, respectively, when the analysis was limited to the 52 countries in the tropical belt). These results indicate that routine influenza immunization efforts should be closely tailored to local patterns of viral circulation, rather than a country's hemispheric position.

Influenza is a major respiratory pathogen with a recognized global disease burden in epidemic and pandemic seasons¹. A constant race between the host immune system and influenza virus evolution requires annual revaccination of populations, in particular the elderly, pregnant women, children, and those with chronic conditions, with periodically updated tri- or quadri-valent influenza vaccines that aim to provide protection against 3 dominant types/subtypes (A/H3, A/H1, B)². Routine vaccinations efforts have been in place for several decades in developed countries to immunize populations before the winter influenza season, while vaccination has recently gained traction in low and middle income countries³⁻⁵.

The World Health Organization (WHO) has established the Global Influenza Surveillance and Response System (GISRS) to inform the WHO influenza vaccine committee, who have met twice a year since 1999 to decide on the antigenic composition of influenza vaccines for the next influenza season in each hemisphere^{6,7}. To establish the Northern Hemisphere (NH) recommendations, globally circulating influenza virus strains are reviewed every February, so that the vaccine can be distributed between September and October, in advance of the winter influenza season. Likewise, for the Southern Hemisphere (SH) recommendations, influenza virus circulation patterns are reviewed each September, so that vaccination usually takes place between March and April of the following year. The current six-month delay between the WHO expert recommendations and vaccine availability is due to limitations of the current technology used in the manufacturing process, which represents a severe challenge for vaccine efficacy. On occasion, the antigen(s) present in the vaccine are mismatched with the circulating strains, causing important vaccine failures⁸, as documented in the recent 2014-15 NH season^{9,10}.

¹National Institutes of Health, Fogarty International Center, Bethesda, MD, 20892, USA. ²Wolfson College, Linton Road, OX26UD, Oxford, UK. ³George Washington University, Milken Institute School of Public Health, Washington, DC 20052, USA. ⁴Evandro Chagas Institute, WHO Global Influenza Surveillance Network, Para, Brazil. Correspondence and requests for materials should be addressed to W.J.A. (email: wladimir.alonso@nih.gov)




Figure 1. Timing of the primary peak of influenza detection (2010–2014), by country, against the latitudinal position of the capital city. The size of points corresponds to the amplitude of influenza seasonality. Colors are used to highlight differences in peak timing. Arrows indicate the typical timing of delivery of the Southern Hemisphere (red) and Northern Hemisphere (blue) vaccines. Countries in the blue and red boxes should adopt the Northern and Southern Hemispheric vaccines, respectively. In each box the area with the darker background highlights countries that should opt for the vaccine recommended for the opposite hemisphere.

Given the current limitations in vaccine production, the goal is to optimize vaccine formulation and timing of administration in each geographic area. This is particularly challenging for tropical regions, where influenza activity are frequently out of phase with the dynamics predicted for their hemispheric group^{11–17}. In fact, recent studies have shown that the optimal timing for routine influenza vaccination recommendations does not correspond to the one expected for their hemisphere in tropical regions of South and Central America^{11,12,17}, Southern and South-Eastern Asia¹⁴, China¹⁵, and Africa^{18,19}. These studies have been important to guide local routine influenza vaccination programs; however these were limited to a handful of countries. Here we extend this approach by mapping influenza seasonality in 125 countries and synthesize available epidemiological evidence to make global vaccine recommendations tailored to the local epidemiology and geography of the disease.

Results

The timing of primary peaks obtained from the 2010–2014 influenza virus circulation time series of each country relative to their capital cities' latitude is shown in Fig. 1. Overall, peak influenza circulation patterns in temperate countries were well aligned with the winter season - mostly between January and February in the Northern Hemisphere (blue and green circles above the northern tropical line in the figure), and July and August in the Southern Hemisphere (bright and dark orange circles below the Southern tropical line in the figure). Conversely, the timing of peak influenza activity in tropical countries had little regard for hemispheric position, and peak influenza activity was distributed unpredictably throughout the year.

Based on the estimated timing of the peak influenza activity, we classified all countries with respect to the vaccine they should adopt (Figs. 1, 2, S1 Table). In total, 26 countries of the Northern Hemisphere should opt for the vaccination recommendation currently targeted at Southern Hemisphere countries (the countries in the shaded area within the red box in Fig. 1 and in Fig. 1: Bhutan, Nepal, Bangladesh, Viet Nam, Dominican Republic, Jamaica, Lao People's Democratic Republic, Senegal, Philippines, Honduras, Thailand, El Salvador, Mali, Nicaragua, Cambodia, Costa Rica, Nigeria, Ethiopia, Panama, Sierra Leone, Côte d'Ivoire, Togo, Colombia, Central African Republic, Cameroon, Uganda). On the other hand, nine countries of Southern Hemisphere (Ecuador, Kenya, Rwanda, Democratic Republic of the Congo, United Republic of Tanzania, Indonesia, Angola, Madagascar, Mozambique) should opt for the vaccine targeted for the Northern Hemisphere (shaded area within the blue box in Fig. 2, Fig. 1 and S1 Table).

Hemisphere	Climate	Recommended vaccination	
		NH	SH
Northern	Temperate	62	3 (5%)
	Tropical	14	23 (62%)
Southern	Tropical	8 (53%)	7
	Temperate	1 (13%)	7

Figure 2. Optimal influenza vaccine recommendations for 125 countries contributing surveillance data (NH: Northern Hemisphere; SH: Southern Hemisphere).

These ‘out-of-phase’ recommendations represent 62% and 53% of countries in the tropical belt of the Northern and Southern Hemisphere. In other words, most countries in this region should receive the vaccine initially recommended for the opposite hemisphere. A few countries with their capital located outside tropical belt (Bhutan, Nepal and Bangladesh in the Northern Hemisphere and Mozambique in the Southern Hemisphere) should also opt for the vaccine for the opposite hemisphere.

Discussion

We have presented here the first global map of hemispheric influenza recommendations based on analysis of laboratory-confirmed epidemiological data for 125 countries. Our results show that, unexpectedly, more than half of the countries in the tropical belt would achieve better vaccine coverage relative to their epidemic patterns by adopting the vaccine formulation developed for the opposite hemisphere. Our data shows that the criteria for determining the most appropriate vaccine recommendation should not depend on the hemispheric location of a country, but instead on local epidemiological information. Such data could be from national influenza surveillance systems or, if such data are not available, from neighboring populations. These findings are of critical importance to countries in these regions that are currently providing, or envisioning, annual influenza vaccine, as failure to adapt vaccine calendars tailored to local circulation patterns is likely to severely impair the success of immunization efforts.

Our study was very inclusive in that we used information from a large and diverse set of countries; however we were limited by the lack of availability of subnational data. Studies in Brazil and China showed the importance of regional heterogeneity in influenza timing in large countries spanning temperate and tropical regions, indicating the need for staggered timing of vaccination^{11,12,15}. Subsequent studies confirmed that these findings were valid for other tropical countries²⁰. Detailed antigenic characterization should also be performed whenever possible in order to carefully study the temporal patterns of emergence of novel drift variants in each hemisphere and each country and the match with vaccine strains (e.g.^{8,21}). It is important to note that seasonality is not well defined (or inexistent) in many tropical regions^{1,19}. Therefore, although our results show the best possible vaccination options based on the data currently available, confidence intervals for the peak timing in those regions would be very broad (despite previous attempts¹¹, the methodology for obtaining confidence intervals in this context is not well established yet). We encourage our readers to inspect and reproduce our analyses using different assumptions and approaches (e.g. using raw data instead of polynomial-detrended data, or consider different time-windows). To this end we have made the underlying epidemiological time series data available at www.epipoi.info/flunet. The free software used for analyses can be downloaded at www.epipoi.info. We also encourage countries with regions in tropical areas to investigate sub-national patterns of influenza and other respiratory virus circulation, to estimate the burden of those pathogens, and how they relate to diverse climatology and connectivity patterns.

Future work to obtain the optimal influenza vaccine match in any country should combine epidemiological and antigenic (and/or phylogenetic) information to evaluate the pathways of virus migration and evolution between regions, countries, and districts. One excellent way to make such data available for analysis would be for WHO's FLUNET database to include information on dominant drift variants were dominant on a weekly or seasonal basis.

Also, further studies should elucidate the social, geographic and demographic factors underlying aberrations in seasonality in some countries¹⁹. The study of population and environmental drivers of influenza circulation should also improve the spatial and temporal resolution of recommendations. Finally, although time series analysis of long-term influenza records can be insightful to hypothesize possible routes of influenza diffusion between states, countries and regions (eg,^{19,24}), precise migration pathways can only be inferred from phylogeographic analyses of influenza viral sequences^{7,23}.

By investigating influenza seasonality for most of the world (including countries that have not been the focus of such analyses before) and making the data and analytical tools used available, we believe this study should contribute to the design of influenza vaccination policies, as well as to further research at national and regional scales.




Figure 3. Heat map of monthly influenza virus incidence patterns in 125 countries, 2009–2014, sorted by latitude of the capital cities. Color bar represents the intensity of influenza incidence, from high (red) to low (blue). Monthly incidence counts were standardized annually, and shown as the proportion of the maximum number of cases in a month for that country and period (hence, months with the maximum number of cases for a given year were assigned the value 1). Year 2009 was excluded from seasonality analyses due to the A/H1N1 pandemic emergence. Data source: FluNet^{5,26}. Visualization: Epipoi²⁸.

Methods

Epidemiological Data. We compiled laboratory-confirmed influenza cases by virus type (seasonal H1N1, H1N1pdm09, H3N2, B and untyped) for 144 countries from the FluNet database, the global influenza surveillance system maintained by WHO^{25,26} (http://www.who.int/influenza/gisrs_laboratory/flunet/en). There was a surge of virus-surveillance after the 2009 influenza pandemic; therefore, we focused on the post-pandemic period 2010–2014 (Fig. 3), when reporting was stable and stronger (2009 was excluded because it was markedly atypical, and 2015 because it is incomplete at the time of this writing). Information was not available at the sub-national level, therefore we generated monthly influenza time-series for each country, with at least 20 virus specimens reported for this period. We also excluded Brazil, India and China as they are large countries spanning temperate and tropical regions, where sub-national studies were previously carried out^{11,12,15}. A total of 125 countries qualified for these analyses.

Statistical Analyses. For each country, we performed time-series analyses to infer the month of peak timing of influenza circulation. For each time-series, we first obtained the periodic annual function (PAF) of the epidemiological time series after de-trending with a quadratic polynomial, and summing up the annual, semi-annual and quarterly harmonics as obtained by Fourier decomposition^{11,27,28}. The timing of the primary (major) peak of the PAF was obtained, and plotted against the latitude of each country's capital (S1 Table), so as to compare the timing of peak influenza activity against that of the two hemispheric vaccine recommendations. Then, we determined whether each country should adopt the NH or SH hemisphere vaccine recommendation. We reasoned that the optimal strategy for any country was to use the most recently available vaccine formulation with respect to local peak influenza timing, as long as the vaccine was available at least two months prior to the peak (early April for the SH formulation, early October for the NH formulation). We estimated two months as the minimum amount of time required to ensure proper vaccine delivery and immunization, and develop immunity. Analyses and figures were generated using the freely available analytical software EpiPOI²⁸.

References

1. Simonsen, L. The global impact of influenza on morbidity and mortality. *Vaccine* **17**, Suppl 1, S3–10 (1999).
2. Vaccines against influenza WHO position paper – November 2012. *Relevé Épidémiologique Hebd. Sect. Hygiène Secrétariat Société Nations Wkly. Epidemiol. Rec. Health Sect. Secr. Leag. Nations* **87**, 461–476 (2012).
3. McAnerney, J. M. *et al.* Effectiveness and knowledge, attitudes and practices of seasonal influenza vaccine in primary healthcare settings in South Africa, 2010–2013. *Influenza Other Respir. Viruses* **9**, 143–150 (2015).
4. Blank, P. R., Bonnelye, G., Ducastel, A. & Szucs, T. D. Attitudes of the General Public and General Practitioners in Five Countries towards Pandemic and Seasonal Influenza Vaccines during Season 2009/2010. *PLoS ONE* **7**, e45450 (2012).
5. WHO, UNICEF & World Bank. *State of the World's Vaccines and Immunization*. (World Health Organization, 2009). <<http://www.who.int/immunization/sowwi/en/>>
6. Kitler, M. E., Gavinio, P. & Lavanchy, D. Influenza and the work of the World Health Organization. *Vaccine* **20**, Suppl 2, S5–14 (2002).
7. Russell, C. A. *et al.* Influenza vaccine strain selection and recent studies on the global migration of seasonal influenza viruses. *Vaccine* **26**, Suppl 4, D31–34 (2008).
8. Richard, S. A., Viboud, C. & Miller, M. A. Evaluation of Southern Hemisphere influenza vaccine recommendations. *Vaccine* **28**, 2693–2699 (2010).
9. McNeil, S. A. *et al.* Interim estimates of 2014/15 influenza vaccine effectiveness in preventing laboratory-confirmed influenza-related hospitalisation from the Serious Outcomes Surveillance Network of the Canadian Immunization Research Network, January 2015. *Euro Surveill. Bull. Eur. Sur Mal. Transm. Eur. Commun. Dis. Bull.* **20**, 21024 (2015).
10. Skowronski, D. M. *et al.* Interim estimates of 2014/15 vaccine effectiveness against influenza A(H3N2) from Canada's Sentinel Physician Surveillance Network, January 2015. *Euro Surveill. Bull. Eur. Sur Mal. Transm. Eur. Commun. Dis. Bull.* **20** (2015).
11. Alonso, W. J. *et al.* Seasonality of Influenza in Brazil: A Traveling Wave from the Amazon to the Subtropics. *Am. J. Epidemiol.* **165**, 1434–1442 (2007).
12. Mello, W. A. de *et al.* The Dilemma of Influenza Vaccine Recommendations when Applied to the Tropics: The Brazilian Case Examined Under Alternative Scenarios. *PLoS ONE* **4**, e5095 (2009).
13. Bloom-Feshbach, K. *et al.* Latitudinal Variations in Seasonal Activity of Influenza and Respiratory Syncytial Virus (RSV): A Global Comparative Review. *PLoS ONE* **8**, e54445 (2013).
14. Chadha, M. S. *et al.* Dynamics of Influenza Seasonality at Sub-Regional Levels in India and Implications for Vaccination Timing. *PLoS ONE* **10**, e0124122 (2015).
15. Yu, H. *et al.* Characterization of Regional Influenza Seasonality Patterns in China and Implications for Vaccination Strategies: Spatio-Temporal Modeling of Surveillance Data. *PLoS Med* **10**, e1001552 (2013).
16. Saha, S. *et al.* Influenza seasonality and vaccination timing in tropical and subtropical areas of southern and south-eastern Asia. *Bull. World Health Organ.* **92**, 318–330 (2014).
17. Ropero-Álvarez, A. M., Kurtis, H. J., Danovaro-Holliday, M. C., Ruiz-Matus, C. & Andrus, J. K. Expansion of seasonal influenza vaccination in the Americas. *BMC Public Health* **9**, 361 (2009).
18. Heraud, J.-M. *et al.* Spatiotemporal Circulation of Influenza Viruses in 5 African Countries During 2008–2009: A Collaborative Study of the Institut Pasteur International Network. *J. Infect. Dis.* **206**, S5–S13 (2012).
19. Alonso, W. J. *et al.* Influenza seasonality in Madagascar: the mysterious African free-runner. *Influenza Other Respir. Viruses* **9**, 101–109 (2015).
20. Chadha, M. S. *et al.* Dynamics of Influenza and Implications for Vaccination Timing. *PLoS ONE* **8**, e54445 (2015).
21. Alonso, W. J. *et al.* Different from equatorial Brazil, Southern Hemisphere WHO vaccination recommendations are adequate for most of southern parts of Brazil. In *Supplement to The American Journal of Tropical Medicine and Hygiene* **91**, 541 (American Society of Tropical Medicine and Hygiene, 2014).
22. Viboud, C., Alonso, W. J. & Simonsen, L. Influenza in Tropical Regions. *PLoS Med* **3**, e89 (2006).
23. Lemey, P. *et al.* Unifying Viral Genetics and Human Transportation Data to Predict the Global Transmission Dynamics of Human Influenza H3N2. *PLoS Pathog* **10**, e1003932 (2014).
24. Viboud, C. *et al.* Synchrony, Waves, and Spatial Hierarchies in the Spread of Influenza. *Science* **312** (2006).
25. Flahault, A. *et al.* FluNet as a tool for global monitoring of influenza on the Web. *Jama* **280**, 1330–2 (1998).
26. He, D. *et al.* Global Spatio-temporal Patterns of Influenza in the Post-pandemic Era. *Sci. Rep.* **5** (2015).
27. Rogers, D. J., Hay, S. I. & Packer, M. J. Predicting the distribution of tsetse flies in West Africa using temporal Fourier processed meteorological satellite data. *Ann Trop Med Parasitol* **90**, 225–241 (1996).
28. Alonso, W. J. & McCormick, B. J. EPIPOI: A user-friendly analytical tool for the extraction and visualization of temporal parameters from epidemiological time series. *BMC Public Health* **12**, 982 (2012).

Acknowledgements

Funding for this project comes from the Office of Pandemics and Emerging Threats of the Department of Health and Human Services (WJA, CV, MM) and from the RAPIDD program of the Science & Technology Directorate, Department of Homeland Security US, the Lundbeck Foundation, Denmark, and a Marie Skłodowska-Curie Senior Fellowship award (H2020-MSCA-IF-2014, project id 6594) (LS).

Author Contributions

W.J.A. conceived and designed the study, analysed the data and wrote the manuscript. C.Y. analysed the data and wrote the manuscript. C.V., S.A.R., C.S.P., L.S., W.A.M. and M.A.M. wrote the manuscript.

Additional Information

Supplementary information accompanies this paper at <http://www.nature.com/srep>

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Alonso, W. J. *et al.* A global map of hemispheric influenza vaccine recommendations based on local patterns of viral circulation. *Sci. Rep.* **5**, 17214; doi: 10.1038/srep17214 (2015).



This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>